Anti-EBLN1 monoclonal antibody

Pre-made anti-EBLN1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to EBLN1/EBLN1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0735-Ab-1/ GM-Tg-hg-IP0735-Ab-2Anti-Human EBLN1 monoclonal antibodyHuman
GM-Tg-rg-IP0735-Ab-1/ GM-Tg-rg-IP0735-Ab-2Anti-Rat EBLN1 monoclonal antibodyRat
GM-Tg-mg-IP0735-Ab-1/ GM-Tg-mg-IP0735-Ab-2Anti-Mouse EBLN1 monoclonal antibodyMouse
GM-Tg-cynog-IP0735-Ab-1/ GM-Tg-cynog-IP0735-Ab-2Anti-Cynomolgus/ Rhesus macaque EBLN1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0735-Ab-1/ GM-Tg-felg-IP0735-Ab-2Anti-Feline EBLN1 monoclonal antibodyFeline
GM-Tg-cang-IP0735-Ab-1/ GM-Tg-cang-IP0735-Ab-2Anti-Canine EBLN1 monoclonal antibodyCanine
GM-Tg-bovg-IP0735-Ab-1/ GM-Tg-bovg-IP0735-Ab-2Anti-Bovine EBLN1 monoclonal antibodyBovine
GM-Tg-equg-IP0735-Ab-1/ GM-Tg-equg-IP0735-Ab-2Anti-Equine EBLN1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0735-Ab-1/ GM-Tg-hg-IP0735-Ab-2; GM-Tg-rg-IP0735-Ab-1/ GM-Tg-rg-IP0735-Ab-2;
GM-Tg-mg-IP0735-Ab-1/ GM-Tg-mg-IP0735-Ab-2; GM-Tg-cynog-IP0735-Ab-1/ GM-Tg-cynog-IP0735-Ab-2;
GM-Tg-felg-IP0735-Ab-1/ GM-Tg-felg-IP0735-Ab-2; GM-Tg-cang-IP0735-Ab-1/ GM-Tg-cang-IP0735-Ab-2;
GM-Tg-bovg-IP0735-Ab-1/ GM-Tg-bovg-IP0735-Ab-2; GM-Tg-equg-IP0735-Ab-1/ GM-Tg-equg-IP0735-Ab-2
Products NameAnti-EBLN1 monoclonal antibody
Formatmab
Target NameEBLN1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-EBLN1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0735-Ag-1Recombinant multi-species EBLN1/ EBLN-1 protein


    Target information

    Target IDGM-IP0735
    Target NameEBLN1
    Gene ID340900,120095344,100426702
    Gene Symbol and SynonymsEBLN-1,EBLN1
    Uniprot AccessionP0CF75
    Uniprot Entry NameEBLN1_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000223601
    Target ClassificationN/A

    The target: EBLN1, gene name: EBLN1, also named as EBLN-1. 0.



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.